Demand for next-generation GLP-1 drugs is fueling a boom in peptide research, prompting companies like Sai Life Sciences to expand capabilities amid a hot market for obesity and diabetes treatments. “The GLP-1 agonists have exploded the peptide field,” said Maneesh Pingle, Ph.D., executive vice president and head of discovery services at Sai Life Sciences, in… The post Sai Life Sciences exec: GLP-1 boom has ‘exploded the peptide field’ as firm opens new center appeared first on Drug...| Drug Discovery and Development
At the recent CPHI exhibition in a very wet Milan, you couldn’t move for booths expounding on the capabilities of the world’s manufacturing, services, packaging and ingredients players. Some of these companies formerly considered themselves to be Contract Research Organisations (CROs) or CMOs (Contract Manufacturing Organisations) but now proudly display the letters CDMO (Contract Development […] The post CDMOs: A Paradigm Change for Pharma? appeared first on Evaluate.| Evaluate
If you missed it, the recording is available here. If you’re short on time, here are three of the key points that I took away from the session. Our speakers included Amanda Micklus from the Norstella consulting team, and Vince Spurr, one of our CDMO experts. Perhaps more importantly, we were joined by Matt Hewitt […] The post In Case You Missed It: Three Things We Learned in Our CDMO Webinar appeared first on Evaluate.| Evaluate
There are two inflection points where a pharma or biotech company looks to a CDMO. In one instance, it’s a technology transfer to create regional or incremental capacity, helping reduce the risk of a single-source manufacturing process. While this isn’t risk-free, it’s relatively straightforward. In recent years, though, we’ve seen an increase in companies seeking […] The post In Sickness and in Health: The CDMO/Pharma Relationship appeared first on Evaluate.| Evaluate
CDMOs (Contract Development and Manufacturing Organisations) are key players in the biopharma market, playing a vital role in translating science into medicines that change people’s lives. Almost all pharma and biotech companies rely on CDMO services to some extent, whether that’s for clinical trials or huge marketed drugs. However, CDMOs view the market through a […] The post CDMO Focus: Three Areas to Drive Success appeared first on Evaluate.| Evaluate